MSB

2.08%

94.0¢ mesoblast limited

Jam it in mate ....soon find out if it works or not...if not jam...

First 224 Last

Share
Profile

Follow
ChewingHands

932 Posts.

129

12/08/20

18:30

Post #: 46491511
Share

Originally posted by kervio: ↑

My understanding is that what they are asking for is a metric and test framework for assessing the quality of each batch of product to ensure that once it is a commercial product, the result for patients is the same as the result of the trial. That paragraph was saying that "how it works" hasn't been adequately demonstrated, and knowing how it works in fine detail allows you to be able to do a quick test on a batch of product and say "yes, this one will work just as good as the trials showed us it would, but this other one here is no good and won't have any effect". That's why the document talks a lot about potency etc.

efficacy = does the product work? (YES!)
mechanism of action = how it works? (need more info)

From the extra information, they want to be able to recommend a benchmark or some standards for regularly testing the product in the marketplace. With most drugs there are existing standards for this kind of thing that can be reused or adapted (like does pill X contain at least YY milligrams of compound Z? because we know that compound Z is what cures headaches/itchy toe/mad FOMO) but for cells this is tricky, because they're not chemicals so you can't pop it in a machine and do a spectrum analysis or whatever they do for their QA usually (I'm not a chemist). They're right to ask the question, and it's something that comes up on these boards from time to time as a point of interest for both bulls and bears on the share. The posters above talking about risk/reward assessment have kind of covered this already, I'd recommend reading what they have to say, though there's only 30 trading minutes before you'll either be very very happy or very very sad, so read fast!

This is my assessment of that bit of the document, I have a scientific background, but not in chemistry or medicine, so google some terms and DYOR.

Expand

Jam it in mate ....soon find out if it works or not...if not jam more in ....Life saved ...done

MSB Price at posting: $3.07 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

VUL

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

There are more pages in this discussion • 268 more messages in this thread...

First 224 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 94.0¢		Change -0.020(2.08%)		Mkt cap ! $1.073B

Open	High	Low	Value	Volume
95.5¢	97.0¢	93.5¢	$1.424M	1.507M

Buyers (Bids)

No.	Vol.	Price($)
8	29390	93.5¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	14089	2

View Market Depth

No.	Vol.	Price($)
6	24054	0.935
8	131583	0.930
4	65851	0.925
7	113334	0.920
9	97006	0.915

Price($)	Vol.	No.
0.945	1100	1
0.950	19026	2
0.955	27000	2
0.960	32869	2
0.965	35384	2

Last trade - 16.10pm 13/09/2024 (20 minute delay)

MSB (ASX) Chart

Jam it in mate ....soon find out if it works or not...if not jam...

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Utah authorities sign off on Anson's lithium extraction plans at Green River

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Jam it in mate ....soon find out if it works or not...if not jam...

Top Stories

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Vulcan appoints investment bank and M&A veteran to board

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Utah authorities sign off on Anson's lithium extraction plans at Green River

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News